

Cover Story
Free
As administrations change, cancer research stands in an unusually strong position, NCI Acting Director Douglas Lowy said in an interview with The Cancer Letter.
In Brief


Funding Opportunities
Drugs & Targets


Trending Stories
- How George Tidmarsh crossed the FDA-industry Rubicon
- Class action complaint alleging GRAIL insider fraud resubmitted after dismissal
- Revolution Medicines’ pancreatic cancer drug received a new priority voucher from FDA
- How GLP-1RA drugs are reshaping patient physiology and the future of oncology
- Cancer centers adapt to life without site visits as NIH changes CCSG review
- CDER Director Tidmarsh quits amid inspector general probe of his “personal conduct”
Cancer advocates express concern about comments that signal trouble for accelerated approval














